Addressing Unmet Needs In Melanoma

ASCO 2022 Conference Coverage
A

Lecture Summary - ASCO 2022 on Anti-PD-1 Antibody: Plus One or Plus Two

By ASCO 2022 Conference Coverage FEATURING Adil Daud
By ASCO 2022 Conference Coverage FEATURING Adil Daud
15 views
August 3, 2022
Comments 0
Login to view comments. Click here to Login
04:49

ASCO 2022 Long-Term Survival in Advanced Melanoma for Pts Treated Wi…

ASCO 2022 Conference Coverage

P. Rutkowski

132 views
05:06

ASCO 2022 on RELATIVITY-047 Trial: Nivolumab + Relatlimab vs. Nivo i…

ASCO 2022 Conference Coverage

P. Rutkowski

1.1K views
16:53

ASCO 2022: Real-World Evaluation of the Association Between Baseline…

ASCO 2022 Conference Coverage

Z. Eroglu

130 views
09:33

ASCO 2022 on ImmunoCobiVem Study Interim Analysis: The Efficacy & Sa…

ASCO 2022 Conference Coverage

E. Livingstone

124 views
07:54

ASCO 2022 Phase II SECOMBIT Study on Optimal Treatment Sequencing in…

ASCO 2022 Conference Coverage

P. Ascierto

110 views
05:48

ASCO 2022 on the Role of Metastasectomy in Advanced BRAF+ Melanoma D…

ASCO 2022 Conference Coverage

K. Orlova

300 views
09:28

ASCO 2022 Meta-Analysis of Randomized Phase II-III Trials Evaluating…

ASCO 2022 Conference Coverage

P. Francesco Ferrucci

110 views
02:01

Lecture Summary - ASCO 2022 Meta-Analysis of Randomized Phase II-III…

ASCO 2022 Conference Coverage

P. Francesco Ferrucci

11 views
06:17

ASCO 2022 Melanoma Updates

Total Health

G. Doolittle

263 views
31:55

Penn Medicine on the Treatment Updates in Melanoma: Head-Spinning Pr…

Penn Medicine Abramson Cancer Center

L. Schuchter

251 views
14:22

ASCO 2022 Nivo + Rela vs. Nivo in Previously Untreated Metastatic/Un…

ASCO 2022 Conference Coverage

E. Lipson

336 views
18:11

ASCO 2022 on Anti-PD-1 Antibody: Plus One or Plus Two

ASCO 2022 Conference Coverage

A. Daud

270 views
10:27

ASCO 2022 Updates on DREAMseq (Doublet, Randomized Evaluation in Adv…

ASCO 2022 Conference Coverage

M. Atkins

215 views